

# **A Sequential Basket Trial Design Based on Multi-Source Exchangeability With Predictive Probability Monitoring**

Alex Kaizer

Assistant Professor  
Department of Biostatistics and Informatics  
Colorado School of Public Health

ENAR 2022  
March 29, 2022



Graduate School

UNIVERSITY OF COLORADO  
DENVER | ANSCHUTZ MEDICAL CAMPUS

# Acknowledgments

Joint work with

- Brian Hobbs (The University of Texas at Austin)
- Nan Chen (Gilead Sciences)
- Emily Zabor (Cleveland Clinic)

Funding:

- K01-HL151754



Graduate School

UNIVERSITY OF COLORADO  
DENVER | ANSCHUTZ MEDICAL CAMPUS

# A Move Towards Precision Medicine in Oncology

- In oncology, studies traditionally are designed for a particular histology or “indication” (e.g., lung cancer)



Graduate School

UNIVERSITY OF COLORADO  
DENVER | ANSCHUTZ MEDICAL CAMPUS

# A Move Towards Precision Medicine in Oncology

- In oncology, studies traditionally are designed for a particular histology or “indication” (e.g., lung cancer)
- We can now partition cancers into many small molecular subtypes and have developed therapies to target these genetic alterations



Graduate School

UNIVERSITY OF COLORADO  
DENVER | ANSCHUTZ MEDICAL CAMPUS

# A Move Towards Precision Medicine in Oncology

- In oncology, studies traditionally are designed for a particular histology or “indication” (e.g., lung cancer)
- We can now partition cancers into many small molecular subtypes and have developed therapies to target these genetic alterations
- However, there may be potential heterogeneity in treatment benefit by indication



Graduate School

































UNIVERSITY OF COLORADO  
DENVER | ANSCHUTZ MEDICAL CAMPUS

# A Move Towards Precision Medicine in Oncology

- In oncology, studies traditionally are designed for a particular histology or “indication” (e.g., lung cancer)
- We can now partition cancers into many small molecular subtypes and have developed therapies to target these genetic alterations
- However, there may be potential heterogeneity in treatment benefit by indication
- Basket trials address this scientific context, but have their own challenges, including interim monitoring for futility (Woodcock and LaVange, 2017; Hobbs et al., 2018)



# Example Basket Trial with 5 Baskets

Scenarios	Basket Number				
	1	2	3	4	5
Global Null 1					
2					
3					
4					
5					
6 Global Alternative					
<b>LEGEND:</b>  Null Basket  Alternative Basket					



Graduate School

UNIVERSITY OF COLORADO  
DENVER | ANSCHUTZ MEDICAL CAMPUS

# Sequential Monitoring for Futility

- 1 Simon's two-stage designs
- 2 Bayesian predictive probability monitoring
- 3 Addition of information sharing across baskets with multi-source exchangeability models (MEMs)



Graduate School

UNIVERSITY OF COLORADO  
DENVER | ANSCHUTZ MEDICAL CAMPUS



# Sequential Monitoring for Futility

- ① Simon's two-stage designs
  - Pros: Simple and easy to implement
  - Cons: Only one interim evaluation, no sharing information across baskets
- ② Bayesian predictive probability monitoring
- ③ Addition of information sharing across baskets with multi-source exchangeability models (MEMs)



# Sequential Monitoring for Futility

- ① Simon's two-stage designs
  - Pros: Simple and easy to implement
  - Cons: Only one interim evaluation, no sharing information across baskets
- ② Bayesian predictive probability monitoring
  - Pros: Can design with more than one interim analysis, interpretation makes sense for interim monitoring
  - Cons: No sharing information across baskets
- ③ Addition of information sharing across baskets with multi-source exchangeability models (MEMs)



# Sequential Monitoring for Futility

- ❶ Simon's two-stage designs
  - Pros: Simple and easy to implement
  - Cons: Only one interim evaluation, no sharing information across baskets
- ❷ Bayesian predictive probability monitoring
  - Pros: Can design with more than one interim analysis, interpretation makes sense for interim monitoring
  - Cons: No sharing information across baskets
- ❸ Addition of information sharing across baskets with multi-source exchangeability models (MEMs)
  - Pros: Can share exchangeable information across baskets
  - Cons: More complex, concerns about heterogeneity
  - We will use an empirically Bayesian prior with a single hyperparameter  $B$ , where  $0 \leq B \leq 1$



Stopping Criteria after Number Observed	Number of Responses Observed														
	Simon Minimax Design					Bayesian Design with 0.1 Threshold					Bayesian Design with 0.2 Threshold				
	0	1	2	3	4	0	1	2	3	4	0	1	2	3	4
5															
6															
7															
8															
9															
10															
11															
12															
13															
14															
15															
16															
17															
18															
19															
20															
21															
22															
23															
24															

Designs assuming a 10% null response and 30% alternative response *without* information sharing calibrated for  $\alpha=0.1$  and 90% power (Simon and Bayesian designs without interim monitoring).

Legend	
	Not evaluated
	Terminate for futility
	Continue enrollment

# Simulation Set-up

Assume a 10 basket trial where  $p_0 = 0.1$  and our target response is  $p_1 = 0.3$

Generate 1,000 trials with  $N = 25$  per basket under two scenarios:

- 1 Global scenario (all null or all alternative baskets)
- 2 Mixed scenario (8 null and 2 alternative baskets)

Compare three designs:

- 1 Simon minimax two-stage design
- 2 Bayesian design with predictive probability monitoring *without* information sharing (i.e.,  $B = 0$ )
- 3 Bayesian design with predictive probability monitoring *with* information sharing via MEMs set at  $B = 0.1$



# Bayesian Calibration and Monitoring

Assume a  $\text{Beta}(0.5,0.5)$  prior on treatment response.

Posterior probability thresholds calibrated to achieve a 10% type I error rate under the **global null scenario** with  $N = 25$  and **no interim monitoring**:


- When  $B = 0$ , conclude “success” if above 0.900.
- When  $B = 0.1$ , conclude “success” if above 0.848.

Predictive probability monitoring for futility is implemented continually after the 5th participant in each basket.


Explore thresholds across a grid of values from 0 to 0.5 in increments of 0.05.



## Rejection Rate




## Rejection Rate







## Rejection Rate




## Expected Sample Size




## Expected Sample Size




## Expected Sample Size




## Stop Rate



## Stop Rate




## Stop Rate




# Mixed Scenario Results


## Rejection Rate



## Expected Size



## Stop Rates



- Null Baskets,  $B=0.1$
- Alternative Baskets,  $B=0.1$
- - Null Baskets,  $B=0$
- - Alternative Baskets,  $B=0$
- ... Null Baskets, Simon
- ... Alternative Baskets, Simon



# Discussion

- Ultimately, there is no free lunch
- The Simon two-stage design is inefficient with respect to many trial operating characteristics, but simple to implement
- Predictive probability monitoring can lead to a much lower expected sample size with only slightly lower power relative to the Simon design
- Information sharing with MEMs can increase power in the global scenario, but should be calibrated if other scenarios are expected (Kaizer et al., 2020)



# Sources I

- Hobbs, B., Kane, M., Hong, D., and Landin, R. (2018). Statistical challenges posed by uncontrolled master protocols: sensitivity analysis of the vemurafenib study. *Annals of Oncology*.
- Kaizer, A. M., Koopmeiners, J. S., Chen, N., and Hobbs, B. P. (2020). Statistical design considerations for trials that study multiple indications. *Statistical Methods in Medical Research*.
- Kaizer, A. M., Koopmeiners, J. S., and Hobbs, B. P. (2017). Bayesian hierarchical modeling based on multi-source exchangeability. *Biostatistics*.
- Woodcock, J. and LaVange, L. M. (2017). Master protocols to study multiple therapies, multiple diseases, or both. *New England Journal of Medicine*, 377(1):62–70.



# Tabular Results-Global Null

PP Thres hold	Rejection Rate		Family-wise Rate		Expected Size		Stop Rate		Prob. All Null Stop	
	B=0	B=0.1	B=0	B=0.1	B=0	B=0.1	B=0	B=0.1	B=0	B=0.1
0	0.096	0.093	0.635	0.559	25.0	25.0	0.000	0.000	0.000	0.000
0.05	0.082	0.081	0.563	0.543	14.8	13.8	0.844	0.851	0.211	0.242
0.1	0.070	0.067	0.508	0.478	11.9	11.2	0.877	0.882	0.282	0.320
0.15	0.061	0.060	0.453	0.442	10.1	10.0	0.898	0.902	0.355	0.393
0.2	0.053	0.050	0.418	0.386	9.6	9.2	0.947	0.950	0.582	0.614
0.25	0.049	0.042	0.391	0.340	9.1	8.5	0.951	0.957	0.609	0.660
0.3	0.042	0.038	0.348	0.295	8.6	8.0	0.958	0.962	0.652	0.705
0.35	0.037	0.031	0.312	0.247	8.1	7.3	0.963	0.969	0.688	0.753
0.4	0.034	0.025	0.297	0.210	7.8	6.8	0.966	0.975	0.703	0.790
0.45	0.028	0.019	0.253	0.166	7.3	6.4	0.972	0.981	0.747	0.834
0.5	0.021	0.017	0.198	0.145	6.7	6.1	0.979	0.983	0.802	0.855



Graduate School

UNIVERSITY OF COLORADO  
DENVER | ANSCHUTZ MEDICAL CAMPUS

# Tabular Results-Global Alternative

PP Thres hold	Rejection Rate		Expected Size		Stop Rate		Prob. All Null Stop	
	B=0	B=0.1	B=0	B=0.1	B=0	B=0.1	B=0	B=0.1
0	0.905	0.971	25.0	25.0	0.000	0.000	0.000	0.000
0.05	0.859	0.925	23.7	24.2	0.111	0.064	0.000	0.000
0.1	0.801	0.896	22.3	23.6	0.178	0.094	0.000	0.000
0.15	0.746	0.869	21.0	23.0	0.239	0.122	0.000	0.000
0.2	0.727	0.844	20.7	22.5	0.273	0.154	0.000	0.000
0.25	0.707	0.824	20.3	22.1	0.293	0.176	0.000	0.000
0.3	0.676	0.802	19.7	21.6	0.324	0.197	0.000	0.000
0.35	0.642	0.779	19.1	21.2	0.358	0.221	0.000	0.000
0.4	0.619	0.760	18.6	20.8	0.381	0.240	0.000	0.000
0.45	0.577	0.743	17.7	20.5	0.423	0.257	0.000	0.000
0.5	0.518	0.721	16.4	20.1	0.482	0.279	0.000	0.000




Graduate School


UNIVERSITY OF COLORADO  
DENVER | ANSCHUTZ MEDICAL CAMPUS

# Global Scenario Results


## Rejection Rate



## Expected Size




## Stop Rates




- Null Baskets, B=0.1
- Alternative Baskets, B=0.1
- - Null Baskets, B=0
- - Alternative Baskets, B=0
- ... Null Baskets, Simon
- ... Alternative Baskets, Simon

# Family-wise Global Scenario Results


## Rejection Rate



## Expected Size




## Stop Rates




- Null Baskets,  $B=0.1$
- Alternative Baskets,  $B=0.1$
- - Null Baskets,  $B=0$
- - Alternative Baskets,  $B=0$
- ..... Null Baskets, Simon
- ..... Alternative Baskets, Simon

# Family-Wise Mixed Scenario Results


## Rejection Rate



## Expected Size



## Stop Rates



- Null Baskets,  $B=0.1$
- Alternative Baskets,  $B=0.1$
- - Null Baskets,  $B=0$
- - Alternative Baskets,  $B=0$
- ... Null Baskets, Simon
- ... Alternative Baskets, Simon


# Multi-Source Exchangeability Models (MEMs)

- A general Bayesian framework to enable incorporation of independent sources of supplemental information based on Bayesian model averaging across all possible combinations of exchangeability (Kaizer et al., 2017)
- Amount of borrowing determined by exchangeability of data (e.g., equivalent response rates)
- Exchangeability priors specified with respect to sources rather than models
- Using an empirical Bayes prior with single hyperparameter  $B$ , where  $0 \leq B \leq 1$





# Standard Analysis (No Borrowing)



## Notation

$y_h$  Observable Data

$\theta_p$  Parameters of Interest





→ Pooled data



Graduate School

UNIVERSITY OF COLORADO  
DENVER | ANSCHUTZ MEDICAL CAMPUS

# MEM Framework



## Notation

$y_h$  Observable Data

$\theta_p$  Parameters of Interest

$\rightarrow$  Pooled data


$\Omega_k$  Model



Graduate School

UNIVERSITY OF COLORADO  
DENVER | ANSCHUTZ MEDICAL CAMPUS

# MEM Framework



## Notation

$y_h$  Observable Data

$\theta_p$  Parameters of Interest

$\rightarrow$  Pooled data

$\Omega_k$  Model

$\omega_k$  Model weight



Graduate School

UNIVERSITY OF COLORADO  
DENVER | ANSCHUTZ MEDICAL CAMPUS

# Building the MEM framework

- MEM framework leverages the concept of Bayesian model averaging
- Posterior model weights are

$$\omega_k = pr(\Omega_k|D) = \frac{p(D|\Omega_k)\pi(\Omega_k)}{\sum_{j=1}^K p(D|\Omega_j)\pi(\Omega_j)},$$

where  $p(D|\Omega_k)$  is the integrated marginal likelihood and  $\pi(\Omega_k)$  is the prior belief that  $\Omega_k$  is the true model

- MEM framework specifies priors with respect to the sources

